Literature DB >> 8793392

Is it important to identify extended-spectrum beta-lactamase-producing isolates?

K Bush.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8793392     DOI： 10.1007/bf01690090

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  38 in total

1.  In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.

Authors:  B Pangon; C Bizet; A Buré; F Pichon; A Philippon; B Regnier; L Gutmann
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

2.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  High-level resistance to cefotaxime and ceftazidime in Klebsiella pneumoniae isolates from Cleveland, Ohio.

Authors:  K S Thomson; C C Sanders; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Importance of organisms producing broad-spectrum SHV-group beta-lactamases into the United Kingdom.

Authors:  K P Shannon; A King; I Phillips; M H Nicolas; A Philippon
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

6.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

7.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

8.  Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.

Authors:  P A Bradford; C E Cherubin; V Idemyor; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

10.  In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

Authors:  B D Jett; D J Ritchie; R Reichley; T C Bailey; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  20 in total

1.  A new SHV-derived extended-spectrum beta-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the -loop.

Authors:  H Kurokawa; T Yagi; N Shibata; K Shibayama; K Kamachi; Y Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit in the high-prevalence area of Athens, Greece.

Authors:  E Lebessi; H Dellagrammaticas; P T Tassios; L S Tzouvelekis; S Ioannidou; M Foustoukou; N J Legakis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Real-time PCR and melting curve analysis for reliable and rapid detection of SHV extended-spectrum beta-lactamases.

Authors:  C C Randegger; H Hächler
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients.

Authors:  R Colodner; W Rock; B Chazan; N Keller; N Guy; W Sakran; R Raz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-19       Impact factor: 3.267

6.  Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases.

Authors:  R Colodner; B Reznik; V Gal; H Yamazaki; H Hanaki; R Kubo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

7.  Extended spectrum beta-lactamase reactions in Stenotrophomonas maltophilia.

Authors:  J Blahová; M Hupková-Lesická; K Králiková; V Krcméry
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

8.  Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12.

Authors:  M T Nüesch-Inderbinen; F H Kayser; H Hächler
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate.

Authors:  Yohei Doi; Naohiro Shibata; Keigo Shibayama; Kazunari Kamachi; Hiroshi Kurokawa; Keiko Yokoyama; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?

Authors:  E S Moland; C C Sanders; K S Thomson
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.